Alkem Laboratories Launches Semaglutide Injection in India, Starting at INR 450 Weekly
Mumbai, March 21, 2026: Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM) announced the launch of semaglutide injection in India under the brand names ‘Semasize’, ‘Obesema’ and ‘Hepaglide’. The medication is for type-2 diabetes mellitus and chronic weight management and administered as a subcutaneous injection once weekly.The pre-filled disposable injection pen is available at a starting price of INR 1,800 for a month's dosage, which translates to a weekly cost of INR 450. Alkem aims to broaden access to this therapy through the affordable pricing.
Alkem has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing semaglutide for type 2 diabetes mellitus and chronic weight management as an adjunct to diet and exercise. Semaglutide is a prescription product and should be taken under appropriate medical supervision.
In addition to the disposable pen, Alkem is also providing a reusable injection pen for semaglutide administration for higher maintenance doses. The reusable pen allows patients to replace only the medication cartridge, reducing cost and supporting treatment adherence.
“We believe therapeutic advancements must translate into real-world access to create a lasting impact,” said Dr. Vikas Gupta, Chief Executive Officer, Alkem. “With the launch of our indigenously-developed semaglutide, we are bringing a high-quality and affordable option to market, empowering healthcare practitioners to offer this therapy to more deserving patients.”
Alkem Laboratories Ltd. is a pharmaceutical company with over 50 years of experience. It holds a position as the sixth largest pharmaceutical company in the Indian market with a strong presence in anti-infectives, gastrointestinal, and pain management. The company has 18 manufacturing facilities and research and development centers across India and the US.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.